Skip to main content
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest
  • facebook
  • twitter
  • linkedin
  • youtube
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest

SonALAsense, Inc.

By jpalfreyman on Thu, 10/26/2023 - 11:48
  • Read more about SonALAsense, Inc.

TenNor Therapeutics (Suzhou) Limited

By jpalfreyman on Thu, 10/26/2023 - 11:43
  • Read more about TenNor Therapeutics (Suzhou) Limited

BioNova Pharmaceuticals (Shanghai) Limited

By jpalfreyman on Thu, 10/26/2023 - 11:31
  • Read more about BioNova Pharmaceuticals (Shanghai) Limited

Evaluation of Concordance Between Exhaled Air Test (eBAM-CoV) and RT-PCR to Detect SARS-CoV-2

  • Read more about Evaluation of Concordance Between Exhaled Air Test (eBAM-CoV) and RT-PCR to Detect SARS-CoV-2

Cardiovascular Complications in Children With COVID 19

  • Read more about Cardiovascular Complications in Children With COVID 19

Effect of Apollo Wearable on Long COVID-19 Symptoms.

  • Read more about Effect of Apollo Wearable on Long COVID-19 Symptoms.

Curadel Surgical Innovations, Inc.

By jpalfreyman on Mon, 10/23/2023 - 15:20
  • Read more about Curadel Surgical Innovations, Inc.

Inspiratory Muscle Training in People With Long COVID-19- A Pilot Investigation.

  • Read more about Inspiratory Muscle Training in People With Long COVID-19- A Pilot Investigation.

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel

  • Read more about Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel

89Zr-DFO-girentuximab Expanded Access Program (EAP)

  • Read more about 89Zr-DFO-girentuximab Expanded Access Program (EAP)

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 94
  • Page 95
  • Page 96
  • Page 97
  • Current page 98
  • Page 99
  • Page 100
  • Page 101
  • Page 102
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Subscribe for updates from the Reagan-Udall Foundation for the FDA

Subscribe
(202) 849 - 2075
1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036
navigator@reaganudall.org
  • facebook
  • twitter
  • linkedin
  • youtube

© Reagan-Udall Foundation for the FDA
© Reagan-Udall Foundation for the FDA